Literature DB >> 26748765

Induced pluripotent stem cells and Parkinson's disease: modelling and treatment.

Xiaoyun Xu1, Jinsha Huang1, Jie Li1, Ling Liu1, Chao Han1, Yan Shen1, Guoxin Zhang1, Haiyang Jiang1, Zhicheng Lin2, Nian Xiong1, Tao Wang1.   

Abstract

Many neurodegenerative disorders, such as Parkinson's disease (PD), are characterized by progressive neuronal loss in different regions of the central nervous system, contributing to brain dysfunction in the relevant patients. Stem cell therapy holds great promise for PD patients, including with foetal ventral mesencephalic cells, human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs). Moreover, stem cells can be used to model neurodegenerative diseases in order to screen potential medication and explore their mechanisms of disease. However, related ethical issues, immunological rejection and lack of canonical grafting protocols limit common clinical use of stem cells. iPSCs, derived from reprogrammed somatic cells, provide new hope for cell replacement therapy. In this review, recent development in stem cell treatment for PD, using hiPSCs, as well as the potential value of hiPSCs in modelling for PD, have been summarized for application of iPSCs technology to clinical translation for PD treatment.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh：

Year:  2016        PMID： 26748765      PMCID： PMC6495331          DOI： 10.1111/cpr.12229

Source DB:  PubMed          Journal:  Cell Prolif        ISSN： 0960-7722            Impact factor:   6.831


  113 in total

Review 1.  Methods for making induced pluripotent stem cells: reprogramming à la carte.

Authors:  Federico González; Stéphanie Boué; Juan Carlos Izpisúa Belmonte
Journal:  Nat Rev Genet       Date:  2011-02-22       Impact factor: 53.242

2.  Development of histocompatible primate-induced pluripotent stem cells for neural transplantation.

Authors:  Michela Deleidi; Gunnar Hargus; Penelope Hallett; Teresia Osborn; Ole Isacson
Journal:  Stem Cells       Date:  2011-07       Impact factor: 6.277

3.  iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease.

Authors:  Chris M Woodard; Brian A Campos; Sheng-Han Kuo; Melissa J Nirenberg; Michael W Nestor; Matthew Zimmer; Eugene V Mosharov; David Sulzer; Hongyan Zhou; Daniel Paull; Lorraine Clark; Eric E Schadt; Sergio Pablo Sardi; Lee Rubin; Kevin Eggan; Mathew Brock; Scott Lipnick; Mahendra Rao; Stephen Chang; Aiqun Li; Scott A Noggle
Journal:  Cell Rep       Date:  2014-11-06       Impact factor: 9.423

4.  Parkin mutations reduce the complexity of neuronal processes in iPSC-derived human neurons.

Authors:  Yong Ren; Houbo Jiang; Zhixing Hu; Kevin Fan; Jun Wang; Stephen Janoschka; Xiaomin Wang; Shaoyu Ge; Jian Feng
Journal:  Stem Cells       Date:  2015-01       Impact factor: 6.277

5.  Genetic animal models for evaluating the role of autophagy in etiopathogenesis of Parkinson disease.

Authors:  M Lenard Lachenmayer; Zhenyu Yue
Journal:  Autophagy       Date:  2012-08-29       Impact factor: 16.016

6.  Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid.

Authors:  Oliver Cooper; Gunnar Hargus; Michela Deleidi; Alexandra Blak; Teresia Osborn; Elizabeth Marlow; Kristen Lee; Adam Levy; Eduardo Perez-Torres; Alyssa Yow; Ole Isacson
Journal:  Mol Cell Neurosci       Date:  2010-07-24       Impact factor: 4.314

7.  Angiogenic and neurotrophic effects of vascular endothelial growth factor (VEGF165): studies of grafted and cultured embryonic ventral mesencephalic cells.

Authors:  Mark R Pitzer; Caryl E Sortwell; Brian F Daley; Susan O McGuire; Deanna Marchionini; Matthew Fleming; Timothy J Collier
Journal:  Exp Neurol       Date:  2003-08       Impact factor: 5.330

Review 8.  The 6-hydroxydopamine model: news from the past.

Authors:  Fabio Blandini; Marie-Therese Armentero; Emilia Martignoni
Journal:  Parkinsonism Relat Disord       Date:  2008-07-02       Impact factor: 4.891

9.  Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons.

Authors:  Maria Sundberg; Helle Bogetofte; Tristan Lawson; Johan Jansson; Gaynor Smith; Arnar Astradsson; Michele Moore; Teresia Osborn; Oliver Cooper; Roger Spealman; Penelope Hallett; Ole Isacson
Journal:  Stem Cells       Date:  2013-08       Impact factor: 6.277

Review 10.  Human-induced pluripotent stem cells: potential for neurodegenerative diseases.

Authors:  Christopher A Ross; Sergey S Akimov
Journal:  Hum Mol Genet       Date:  2014-05-13       Impact factor: 6.150
View more
  4 in total

1.  Induced pluripotent stem cells in rat models of Parkinson's disease: A systematic review and meta-analysis.

Authors:  Yunxia Zhang; Meiling Ge; Qiukui Hao; Birong Dong
Journal:  Biomed Rep       Date:  2018-01-30

Review 2.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

3.  Mitochondrial genome mutations and neuronal dysfunction of induced pluripotent stem cells derived from patients with Alzheimer's disease.

Authors:  Yeonmi Lee; Minchul Kim; Miju Lee; Seongjun So; Soon-Suk Kang; Jiwan Choi; Deokhoon Kim; Hyohoon Heo; Sung Soo Lee; Hee Ra Park; Jung Jae Ko; Jihwan Song; Eunju Kang
Journal:  Cell Prolif       Date:  2022-06-13       Impact factor: 8.755

Review 4.  One Step Into the Future: New iPSC Tools to Advance Research in Parkinson's Disease and Neurological Disorders.

Authors:  Nguyen-Vi Mohamed; Frédérique Larroquette; Lenore K Beitel; Edward A Fon; Thomas M Durcan
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.